ME/CFS research has increasingly focused on mitochondrial dysfunction and abnormal cellular energy metabolism as potential core mechanisms. Several studies have documented elevated blood lactate, impaired oxidative phosphorylation, and reduced mitochondrial function in ME/CFS patients — particularly following exertion.

This metabolic pattern is mechanistically similar to the Warburg effect: a shift toward anaerobic glycolysis and away from efficient mitochondrial ATP production. DCA’s mechanism — reactivating PDH and restoring mitochondrial metabolism — targets exactly this dysfunction.

The potassium salt form has a potential advantage in some ME/CFS contexts. Autonomic dysfunction is common in ME/CFS, and some patients manage sodium intake carefully for cardiovascular reasons. KDCA provides the same dichloroacetate anion without the sodium load.

Published human data on DCA for ME/CFS is very limited — mostly case reports. No controlled trial has been completed. The mechanistic rationale is strong; the clinical evidence base is not yet there. This is an area of genuine research interest.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.